30294 Federal Register / Vol. 74, No. 121 / Thursday, June 25, 2009 / Notices 

TRANSACTION GRANTED—EARLY TERMINATION—Continued 

ET date TRANS No. ET req. 

status Party name 

G Eastern Financial Florida Credit Union. 

G Eastern Financial Florida Credit Union. 

29–MAY–09 ................ 20090442 G John C. Malone. 

G Liberty Global, Inc. 

G Liberty Global, Inc. 

01–JUN–09 ................ 20090454 G GlaxoSmithKline plc. 

G Stiefel Laboratories, Inc. 

G Stiefel Laboratories, Inc. 

20090473 G Mr. James Laurence Balsillie. 

G Mr. Jerry Moyes. 

G Coyotes Hockey, LLC. 

20090480 G Green Plains Renewable Energy, Inc. 

G RBF Acquisition II, LLC. 

G RBF Acquisition II, LLC. 

20090482 G Lime Rock Partners V, LP. 

G Allis-Chalmers Energy Inc. 

G Allis-Chalmers Energy Inc. 

20090488 G Aurora Resurgence Fund (C) L.P. 

G Norwood Promotional Products Holdings, Inc. 

G Norwood Promotional Products, Inc. 

02–JUN–09 ................ 20090465 G United Technologies Corporation. 

G Watsco, Inc. 

G Watsco, Inc. 

20090466 G Watsco, Inc. 

G United Technologies Corporation. 

G Carrier Sales and Distribution, LLC. 

05–JUN–09 ................ 20090489 G TC PipeLines, LP. 

G TransCanada Corporation. 

G North Baja Pipeline, LLC. 

20090497 G BioMarin Pharmaceutical Inc. 

G Medicis Pharmaceutical Corporation. 

G Medicis Pediatrics, Inc. 

20090500 G Windstream Corporation. 

G D&E Communications, Inc. 

G D&E Communications, Inc. 

FOR FURTHER INFORMATION CONTACT: 

Sandra M. Peay, Contact Representative, 

or Renee Hallman, Contact 

Representative. Federal Trade 

Commission, Premerger Notification 

Office, Bureau of Competition, Room 

H–303, Washington, DC 20580, (202) 

326–3100. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. E9–14919 Filed 6–24–09; 8:45 am] 

BILLING CODE 6750–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Pandemic Influenza Vaccines— 

Amendment 

Authority: 42 U.S.C. 247d–6d. 

ACTION: Notice of third amendment to 

the January 26, 2007 Declaration under 

the Public Readiness and Emergency 

Preparedness Act, and Republication of 

the Declaration, as Amended. 

SUMMARY: Amendment to declaration 

pursuant to section 319F–3 of the Public 

Health Service Act (42 U.S.C. 247d–6d) 

to provide targeted liability protections 

for pandemic countermeasures based on 

the Acting Secretary’s determination, 

under section 319F–3(b) of the Act, that 

the risk that the spread of H1N1 swine 

influenza viruses (now known as 2009 

H1N1 Influenza A, or 2009 H1N1 

influenza) and resulting disease 

constitutes a public health emergency; 

and republication of the declaration to 

reflect the declaration in its entirety, as 

amended. 

DATES: The third amendment and 

republication of the declaration are 

effective as of June 15, 2009. 

FOR FURTHER INFORMATION CONTACT: 

RADM W.C. Vanderwagen, Assistant 

Secretary for Preparedness and 

Response, Office of the Secretary, 

Department of Health and Human 

Services, 200 Independence Avenue, 

SW., Washington, DC 20201, Telephone 

(202) 205–2882 (this is not a toll-free 

number). 

HHS Secretary’s Amendment to the 

Declaration for the Use of the Public 

Readiness and Emergency 

Preparedness Act for H5N1, H2, H6, 

and H9 Vaccines 

Whereas, on April 26, 2009, Acting 

Secretary Charles Johnson determined 

under section 319 of the Public Health 

Service Act, (42 U.S.C. 247d) (‘‘the 

Act’’), that a public health emergency 

exists nationwide involving the Swine 

influenza A virus that affects or has 

significant potential to affect the 

national security (‘‘2009 H1N1 

influenza’’); 

Whereas, the World Health 

Organization has established a 

Pandemic alert phase 5 for the 2009 

H1N1 influenza virus currently 

circulating worldwide; 

Whereas, vaccination may be effective 

to protect persons from the threat of 

2009 H1N1 influenza; 

Whereas, Secretary Michael O. Leavitt 

issued a Declaration for the Use of the 

Public Readiness and Emergency 

Preparedness Act dated January 26, 

2007 (‘‘Original Declaration’’), as 

amended on November 30, 2007 and 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 74, No. 121 / Thursday, June 25, 2009 / Notices 30295 

October 17, 2008 with respect to certain 

avian influenza viruses; minor 

modifications are necessary to correct 

previous, minor, editorial errors; and 

republication of the Original 

Declaration, as amended, in its entirety 

is necessary for clarity; 

Whereas, the findings made by the 

Secretary in the Original Declaration, as 

amended, continue to apply generally, 

and apply with equal force as to the 

2009 H1N1 influenza; 

Whereas, in accordance with section 

319F–3(b)(6) of the Act (42 U.S.C. 247d– 

6d(b), I have considered the desirability 

of encouraging the design, development, 

clinical testing or investigation, 

manufacturing, labeling, distribution, 

formulation, packaging, marketing, 

promotion, sale, purchase, donation, 

dispensing, prescribing, administration, 

licensing, and use of additional covered 

countermeasures with respect to the 

category of disease and population 

described in sections II and IV of the 

Original Declaration, as amended, and 

as hereby further amended, and have 

found it desirable to encourage such 

activities for these additional covered 

countermeasures, and; 

Whereas, to encourage the design, 

development, clinical testing or 

investigation, manufacturing and 

product formulation, labeling, 

distribution, packaging, marketing, 

promotion, sale, purchase, donation, 

dispensing, prescribing, administration, 

licensing, and use of medical 

countermeasures with respect to the 

category of disease and population 

described in sections II and IV of the 

Original Declaration, as amended, and 

as hereby further amended, it is 

advisable, in accordance with section 

319F–3(a) and (b) of the Act, to provide 

immunity from liability for covered 

persons, as that term is defined at 

section 319F–3(i)(2) of the Act, and to 

include as such covered persons other 

qualified persons as I have identified in 

section VI of the Original Declaration, as 

amended; 

Therefore, pursuant to section 319F– 

3(b) of the Act, I have determined that 

2009 H1N1 influenza and resulting 

disease constitutes a public health 

emergency. In order to extend the 

Original Declaration, as amended, to 

apply to the 2009 H1N1 influenza and 

to correct previous, minor, editorial 

errors, the Original Declaration, as 

amended, is hereby further amended 

and republished as follows: 

In the title, strike ‘‘and H9’’ and insert 

‘‘H9, and 2009 H1N1’’. 

In the first ‘‘whereas’’ clause, first 

sentence, strike ‘‘(H5N1). H7 and H9 

vaccines’’ and insert ‘‘H5N1, H7, and 

H9’’. 

After the fourth ‘‘whereas’’ clause, 

insert a new recital as follows: 

Whereas, on April 26, 2009, Acting 

Secretary Charles E. Johnson 

determined under section 319 of the 

Public Health Service Act, (42 U.S.C. 

247d), that a public emergency exists 

nationwide involving the 2009 H1N1 

influenza virus that affects or has 

significant potential to affect the 

national security (now called ‘‘2009 

H1N1 influenza’’); 

In the ninth ‘‘whereas’’ clause, insert 

‘‘,’’ after ‘‘IV’’; strike ‘‘of the Original 

Declaration, as amended,’’; insert ‘‘;’’ 

after ‘‘VI’’; and strike ‘‘of the Original 

Declaration;’’. 

In the ‘‘therefore’’ clause concluding 

the recitals, strike the period and insert 

‘‘, and that the 2009 H1N1 influenza 

constitutes a public health emergency.’’. 

In section I, second paragraph, first 

sentence, strike all after ‘‘influenza A’’ 

and insert ‘‘H5N1, H2, H6, H7, H9, and 

2009 H1N1 vaccines and any associated 

adjuvants.’’. 

In section I, second paragraph, second 

sentence, strike all after ‘‘influenza A’’ 

and insert ‘‘H5N1, H2, H6, H7, H9, and 

2009 H1N1 vaccines used and 

administered in accordance with this 

declaration.’’. 

Strike the current section II, ‘‘Category 

of Disease,’’ in its entirety and replace 

as follows: 

II. Category of Disease (as Required by 

Section 319F–3(b)(2)(A) of the Act) 

The category of disease for which I am 

recommending the administration or 

use of the Covered Countermeasures is 

the threat of or actual human influenza 

that results from the infection of 

humans following exposure to the virus 

with (1) highly pathogenic avian 

influenza A (H5N1, H2, H6, H7, or H9) 

virus; or (2) 2009 H1N1 influenza. 

In section III, strike the period and 

insert ‘‘; except that with respect to 2009 

H1N1 influenza vaccine, the effective 

period commences on June 15, 2009 and 

extends through March 31, 2013.’’ 

In Section VIII, strike the section in its 

entirety and replace it with the 

following: 

The Declaration for the Use of the 

Public Readiness and Emergency 

Preparedness Act for H5N1 vaccines 

was published on January 26, 2007 and 

amended on November 30, 2007 to add 

H7 and H9 vaccines and on October 17, 

2008 to add H2 and H6 vaccines. This 

Declaration incorporates all 

amendments prior to the date of its 

publication in the Federal Register. Any 

future amendment to this Declaration 

will be published in the Federal 

Register, pursuant to section 319F– 

2(b)(4) of the Act. 

All other provisions of the Original 

Declaration, as amended, remain in full 

force. 

Republication of HHS Secretary’s 

Original Declaration, as Amended, for 

the Use of the Public Readiness and 

Emergency Preparedness Act for H5N1, 

H2, H6, H9, and 2009 H1N1 Vaccines 

To the extent any term of the original 

January 27, 2007 Declaration or any 

amendment thereto is inconsistent with 

any provision of this republished 

Declaration, the terms of this 

republished Declaration are controlling. 

HHS Secretary’s Declaration for the Use 

of the Public Readiness and Emergency 

Preparedness Act for H5N1, H2, H6, H9, 

and 2009 H1N1 Vaccines 

Whereas highly pathogenic avian 

influenza A H5N1, H7, and H9 have 

spread by infected migratory birds and 

exports of live poultry from Asia 

through Europe and Africa since 2004, 

and could spread into North America in 

2006 or later, and have caused disease 

in humans with an associated high case 

fatality upon infection with this virus; 

Whereas, the H2 class of influenza 

viruses, which caused the human 

influenza pandemic of 1957 and 

reappeared recently in U.S. animals 

including swine, is viewed as a likely 

candidate to re-evolve into an influenza 

strain capable of causing a pandemic of 

human influenza; 

Whereas, the H6 class of influenza 

viruses, which appeared recently in 

animals including domestic fowl, is 

viewed as a likely candidate to evolve 

into an influenza strain capable of 

causing a pandemic of human influenza; 

Whereas, an H5N1, H2, H6, H7 or H9 

avian influenza virus may evolve into 

strain capable of causing a pandemic of 

human influenza; 

Whereas, on April 26, 2009, Acting 

Secretary Charles E. Johnson 

determined under section 319 of the 

Public Health Service Act, (42 U.S.C. 

247d), that a public health emergency 

exists nationwide involving the Swine 

Influenza A virus that affects or has 

significant potential to affect the 

national security (now called ‘‘2009 

H1N1 influenza’’); 

Whereas, the possibility of 

governmental program planners 

obtaining stockpiles from private sector 

entities except through voluntary means 

such as commercial sale, donation, or 

deployment would undermine national 

preparedness efforts and should be 

discouraged as provided for in section 

319F–3(b)(2)(E) of the Public Health 

Service Act (42 U.S.C. 247d–6d(b)) (‘‘the 

Act’’); 


sroberts on PROD1PC70 with NOTICES
30296 Federal Register / Vol. 74, No. 121 / Thursday, June 25, 2009 / Notices 

Whereas, immunity under section 

319F–3(a) of the Act should be available 

to governmental program planners for 

distributions of Covered 

Countermeasures obtained voluntarily, 

such as by (1) donation; (2) commercial 

sale; (3) deployment of Covered 

Countermeasures from Federal 

stockpiles; or (4) deployment of 

donated, purchased, or otherwise 

voluntarily obtained Covered 

Countermeasures from State, local, or 

private stockpiles; 

Whereas, the extent of immunity 

under section 319F–3(a) of the Act 

afforded to a governmental program 

planner that obtains Covered 

Countermeasures except through 

voluntary means is not intended to 

affect the extent of immunity afforded 

other covered persons with respect to 

such covered countermeasures; 

Whereas, to encourage the design, 

development, clinical testing or 

investigation, manufacturing and 

product formulation, labeling, 

distribution, packaging, marketing, 

promotion, sale, purchase, donation, 

dispensing, prescribing, administration, 

licensing, and use of medical 

countermeasures with respect to the 

category of disease and population 

described in section II and IV it is 

advisable, in accordance with section 

319F–3(a) and (b) of the Act, to provide 

immunity from liability for covered 

persons, as that term is defined at 

section 319F–3(i)(2) of the Act, and to 

include as such covered persons such 

other qualified persons as I have 

identified in section VI; 

Whereas, in accordance with section 

319F–3(b)(6) of the Public Health 

Service Act (42 U.S.C. 247d–6d(b)) (‘‘the 

Act’’), I have considered the desirability 

of encouraging the design, development, 

clinical testing or investigation, 

manufacturing and product formulation, 

labeling, distribution, packaging, 

marketing, promotion, sale, purchase, 

donation, dispensing, prescribing, 

administration, licensing, and use of 

medical countermeasures with respect 

to the category of disease and 

population described in sections II and 

IV below, and have found it desirable to 

encourage such activities for the 

Covered Countermeasures; 

Therefore, pursuant to section 319F– 

3(b) of the Act, I have determined there 

is a credible risk that the spread of avian 

influenza viruses and resulting disease 

could in the future constitute a public 

health emergency, and that 2009 H1N1 

influenza constitutes a public health 

emergency. 

I. Covered Countermeasures (as 

Required by Section 319F–3(b)(1) of the 

Act) 

Covered Countermeasures are defined 

at section 319F–3(i) of the Act. 

At this time, and in accordance with 

the provisions contained herein, I am 

recommending the manufacture, testing, 

development, distribution, dispensing; 

and, with respect to the category of 

disease and population described in 

sections II and IV, below, the 

administration and usage of the 

pandemic countermeasure influenza A 

H5N1, H2, H6, H7, H9, and 2009 H1N1 

Vaccines and any associated adjuvants. 

The immunity specified in section 

319F–3(a) of the Act shall only be in 

effect with respect to: Present or future 

Federal contracts, cooperative 

agreements, grants, interagency 

agreements, or memoranda of 

understanding for pandemic 

countermeasure influenza A H5N1, H2, 

H6, H7, H9, and 2009 H1N1 vaccines 

used and administered in accordance 

with this declaration. In accordance 

with section 319F–3(b)(2)(E) of the Act, 

for governmental program planners, the 

immunity specified in section 319F–3(a) 

of the Act shall be in effect to the extent 

they obtain Covered Countermeasures 

through voluntary means of 

distribution, such as (1) donation; (2) 

commercial sale; (3) deployment of 

Covered Countermeasures from Federal 

stockpiles; or (4) deployment of 

donated, purchased, or otherwise 

voluntarily obtained Covered 

Countermeasures from State, local, or 

private stockpiles. For all other covered 

persons, including other program 

planners, the immunity specified in 

section 319F–3(a) of the Act shall, in 

accordance with section 319F–3(b)(2)(E) 

of the Act, be in effect pursuant to any 

means of distribution. 

This declaration shall subsequently 

refer to the countermeasures identified 

above as Covered Countermeasures. 

This declaration shall apply to all 

Covered Countermeasures administered 

or used during the effective time period 

of the declaration. 

II. Category of Disease (as Required by 

Section 319F–3(b)(2)(A) of the Act) 

The category of disease for which I am 

recommending the administration or 

use of the Covered Countermeasures is 

the threat of or actual human influenza 

that results from the infection of 

humans following exposure to the virus 

with (1) highly pathogenic avian 

influenza A (H5N1, H2, H6, H7, or H9) 

virus; or (2) 2009 H1N1 influenza. 

III. Effective Time Period (as Required 

by Section 319F–3(b)(2)(B) of the Act) 

The effective period of time of this 

Declaration commences on December 1, 

2006 and extends through February 28, 

2010; except that with respect to 2009 

H1N1 influenza vaccine, the effective 

period commences on June 15, 2009 and 

extends through March 31, 2013. 

IV. Population (as Required by Section 

319F–3(b)(2)(C) of the Act) 

Section 319F–3(a)(4)(A) confers 

immunity to manufacturers and 

distributors of the Covered 

Countermeasure, regardless of the 

defined population. 

Section 319F–3(a)(3)(C)(i) confers 

immunity to covered persons who could 

be program planners or qualified 

persons with respect to the Covered 

Countermeasure only if a member of the 

population specified in the declaration 

administers or uses the Covered 

Countermeasure and is in or connected 

to the geographic location specified in 

this declaration, or the program planner 

or qualified person reasonably could 

have believed that these conditions 

were met. 

The populations specified in this 

Declaration are the following: (1) All 

persons who use a Covered 

Countermeasure or to whom such a 

Covered Countermeasure is 

administered as an Investigational New 

Drug in a human clinical trial 

conducted directly by the Federal 

Government, or pursuant to a contract, 

grant or cooperative agreement with the 

Federal Government; (2) all persons 

who use a Covered Countermeasure or 

to whom such a Countermeasure is 

administered in a pre-pandemic phase, 

as defined below; and/or (3) all persons 

who use a Covered Countermeasure, or 

to whom such a Covered 

Countermeasure is administered in a 

pandemic phase, as defined below. 

V. Geographic Area (as Required by 

Section 319F–3(b)(2)(D) of the Act) 

Section 319F–3(a) applies to the 

administration and use of a Covered 

Countermeasure without geographic 

limitation. 

VI. Other Qualified Persons (as 

Required by Section 319F–3(i)(8)(B) of 

the Act) 

With regard to the administration or 

use of a Covered Countermeasure, 

Section 319F–3(i)(8)(A) of the Act 

defines the term ‘‘qualified person’’ as a 

licensed individual who is authorized to 

prescribe, administer, or dispense the 

countermeasure under the law of the 

State in which such Covered 

Countermeasure was prescribed, 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 74, No. 121 / Thursday, June 25, 2009 / Notices 30297 

administered or dispensed. Additional 

persons who are qualified persons 

pursuant to section 319F–3(i)(8)(B) are 

the following: None. 

VII. Additional Time Periods of 

Coverage After Expiration of 

Declaration (as Required by Section 

319F–3(b)(3)(B) of the Act) 

A. I have determined that, upon 

expiration of the applicable time period 

specified in Section III above, an 

additional twelve (12) months is a 

reasonable period to allow for the 

manufacturer to arrange for disposition 

of the Covered Countermeasure, 

including the return of such product to 

the manufacturer, and for covered 

persons to take such other actions as are 

appropriate to limit the administration 

or use of the Covered Countermeasure, 

and the liability protection of section 

319F–3(a) of the Act shall extend for 

that period. 

B. The Federal Government shall 

purchase the entire production of 

Covered Countermeasures under the 

contracts specifically listed by contract 

number in section I for the stockpile 

under section 319F–2 of the Act, and 

shall be subject to the time-period 

extension of section 319F–3(b)(3)(C). 

Production under future contracts for 

the same vaccine will also be subject to 

the time-period extension of section 

319F–3(b)(3)(C). 

VIII. Amendments 

The Declaration for the Use of the 

Public Readiness and Emergency 

Preparedness Act for H5N1 vaccines 

was published on January 26, 2007 and 

amended on November 30, 2007 to add 

H7 and H9 vaccines and on October 17, 

2008 to add H2 and H6 vaccines. This 

Declaration incorporates all 

amendments prior to the date of its 

publication in the Federal Register. Any 

future amendment to this Declaration 

will be published in the Federal 

Register, pursuant to section 319F– 

2(b)(4) of the Act. 

IX. Definitions 

For the purposes of this declaration, 

‘‘pre-pandemic phase’’ means the 

following stages, as defined in the 

National Strategy for Pandemic 

Influenza: Implementation Plan 

(Homeland Security Council, May 

2006): (0) New Domestic Animal 

Outbreak in At-Risk Country; (1) 

Suspected Human Outbreak Overseas; 

(2) Confirmed Human Outbreak 

Overseas; and (3) Widespread Human 

Outbreaks in Multiple Locations 

Overseas. For the purposes of this 

declaration, ‘‘pandemic phase’’ means 

the following stages, as defined in the 

National Strategy for Pandemic 

Influenza: Implementation Plan 

(Homeland Security Council, May 

2006): (4) First Human Case in North 

America; and (5) Spread Throughout 

United States. 

Dated: June 15, 2009. 

Kathleen Sebelius, 

Secretary. 

Appendix 

I. List of U.S. Government Contracts— 

Covered H5N1 Vaccine Contracts 

[January 26, 2007] 

1. HHSN266200400031C 

2. HHSN266200400032C 

3. HHSN266200300039C 

4. HHSN266200400045C 

5. HHSN266200205459C 

6. HHSN266200205460C 

7. HHSN266200205461C 

8. HHSN266200205462C 

9. HHSN266200205463C 

10. HHSN266200205464C 

11. HHSN266200205465C 

12. HHSN266199905357C 

13. HHSN266200300068C 

14. HHSN266200005413C 

15. HHSO100200600021C (formerly 

200200409981) 

16. HHSO100200500004C 

17. HHSO100200500005I 

18. HHSO100200700026I 

19. HHSO100200700027I 

20. HHSO100200700028I 

21. HHSO100200600010C 

22. HHSO100200600011C 

23. HHSO100200600012C 

24. HHSO100200600013C 

25. HHSO100200600014C 

26. HHSO100200600022C (formerly 

200200511758) 

27. HHSO100200600023C (formerly 

200200410431) 

28. CRADA No. AI–0155 NIAID/ 

MedImmune 

29. HHSO100200700029C 

30. HHSO100200700030C 

31. HHSO100200700031C 

[FR Doc. E9–14948 Filed 6–24–09; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–09–09BX] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. 

Alternatively, to obtain a copy of the 

data collection plans and instrument, 

call 404–639–5960 and send comments 

to Maryam I. Daneshvar, CDC Reports 

Clearance Officer, 1600 Clifton Road, 

NE., MS–D74, Atlanta, Georgia 30333; 

comments may also be sent by e-mail to 

omb@cdc.gov. 

Comments are invited on (a) whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have a 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarify of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of information technology. Written 

comments should be received within 60 

days of this notice. 

Proposed Project 

Clostridium difficile Infection (CDI) 

Surveillance—New—National Center for 

Preparedness, Detection, and Control of 

Infectious Diseases (NCPDCID), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

Steady increases in the rate and 

severity of Clostridium difficile infection 

(CDI) indicate a clear need to conduct 

longitudinal assessments of the impact 

of CDI in the United States. C. difficile 

is an anaerobic, spore-forming, gram 

positive bacillus that produces two 

pathogenic toxins: A and B. CDI ranges 

in severity from mild diarrhea to 

fulminant colitis and death. 

Transmission of C. difficile occurs 

primarily in healthcare facilities, where 

environmental contamination by C. 

difficile spores and exposure to 

antimicrobial drugs are common. No 

longer limited to healthcare 

environments, community-associated 

CDI is the focus of increasing attention. 

Recently, several cases of serious CDI 

have been reported in what have been 

considered low-risk populations, 

including healthy persons living in the 

community and peri-partum women. 

For this proposed data collection, the 

surveillance population will consist of 

persons residing in the catchment area 

of the participating Emerging Infections 

Program (EIP) sites. This surveillance 

poses no more than minimal risk to the 

study participants as there will be no 

interventions or modifications to the 

care study participants receive. EIP 

surveillance personnel will perform 

active case finding from laboratory 

reports of stool specimens testing 


sroberts on PROD1PC70 with NOTICES